"Phenylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the amino-N-phenylamide structure.
Descriptor ID |
D010671
|
MeSH Number(s) |
D02.455.426.559.389.703 D02.948.681
|
Concept/Terms |
Phenylurea Compounds- Phenylurea Compounds
- Compounds, Phenylurea
- Phenylurea Derivatives
- Derivatives, Phenylurea
- Phenylcarbamides
|
Below are MeSH descriptors whose meaning is more general than "Phenylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Phenylurea Compounds".
This graph shows the total number of publications written about "Phenylurea Compounds" by people in this website by year, and whether "Phenylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
2005 | 0 | 2 | 2 |
2007 | 2 | 1 | 3 |
2008 | 0 | 2 | 2 |
2009 | 0 | 4 | 4 |
2010 | 0 | 4 | 4 |
2011 | 0 | 3 | 3 |
2016 | 2 | 0 | 2 |
2017 | 3 | 0 | 3 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenylurea Compounds" by people in Profiles.
-
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022 06 01; 28(11):2270-2277.
-
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. Curr Opin Oncol. 2021 05 01; 33(3):252-256.
-
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol. 2018 01; 81(1):195-206.
-
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. Thyroid. 2017 09; 27(9):1118-1127.
-
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. J Neurooncol. 2017 Jun; 133(2):435-442.
-
A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2016 Aug 05; 784:1-14.
-
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016 Apr 12; 7(15):20080-92.
-
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
-
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
-
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011 Mar 01; 11(5):524-34.